Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma

Daniel W Visscher, Fazlul H. Sarkar, Rie K. Shimoyama, John D. Crissman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We performed p53 immunostaining in 82 invasive breast carcinomas by using two commercially available antibodies, one of which (DO7) was employed in formalin-fixed paraffin-embedded sections. The other antibody (PAb1801) was evaluated in corresponding acetone-fixed cryostat sections. A greater percent of cases were immunostained with DO7 compared to PAb1801 (52% vs 33%); however, the staining was more often heterogeneous (6-50% cells positive) or focal (≤5% cells positive) with DO7 (9% vs 31%). To investigate the genetic relevance of p53 immunostaining, single-strand conformational polymorphism (SSCP) analysis and DNA sequencing were performed on exons 2-11 by using archival tissue samples of 18 cases that were selected on the basis of certain immunostaining patterns. Two (33%) of six tumors with negative staining for DO7 had gene sequence mutations; however, one of these mutations was a base-pair deletion that caused a reading-frame shift and the other was a base-pair insertion that resulted in a stop codon. Both of these tumors exhibited immunostaining with PAb1801, although it was weak and cytoplasmic in one case. Conversely, three (30%) of 10 tumors showing immunoreactivity in 6-100% of cells with both reagents lacked a gene sequence mutation. Of the remaining seven tumors that were positive by SSCP, six contained a point mutation resulting in a base-pair substitution. Despite repeat analyses, one of the cases positive by SSCP failed to demonstrate a mutation in the sequenced exons. Four (80%) of five cases with heterogeneous DO7 immunoreactivity (that is, 6-50% of nuclei positive) were positive for gene sequence mutation. Neither of two cases showing focal DO7 nuclear staining in <5% of tumor cells contained a mutation in the sequenced exons, and neither of these cases was strongly positive with PAb1801. Staining for either antibody was significantly associated with adverse outcome, as determined by disease recurrence at 52 months median follow-up (DO7, p = 0.01; and PAb1801, p = 0.002, chi-squared test). We conclude that a variety of factors may account for discrepancies when immunohistology is used to evaluate p53 status. These include fixation artifacts, differing epitope specificities of monoclonal reagents, presence of immunohistologically 'silent' mutations and, possibly, aberrant overexpression of wild-type protein.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalDiagnostic Molecular Pathology
Volume5
Issue number3
DOIs
StatePublished - Sep 1996
Externally publishedYes

Fingerprint

Breast Neoplasms
Mutation
Base Pairing
Genes
Exons
Neoplasms
Staining and Labeling
Antibodies
Negative Staining
Reading Frames
Terminator Codon
Acetone
DNA Sequence Analysis
Point Mutation
Paraffin
Artifacts
Formaldehyde
Epitopes
Recurrence
Proteins

Keywords

  • Breast carcinoma
  • p53 immunohistochemistry
  • SSCP analysis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. / Visscher, Daniel W; Sarkar, Fazlul H.; Shimoyama, Rie K.; Crissman, John D.

In: Diagnostic Molecular Pathology, Vol. 5, No. 3, 09.1996, p. 187-193.

Research output: Contribution to journalArticle

Visscher, Daniel W ; Sarkar, Fazlul H. ; Shimoyama, Rie K. ; Crissman, John D. / Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. In: Diagnostic Molecular Pathology. 1996 ; Vol. 5, No. 3. pp. 187-193.
@article{7823c272b8b34b449017c7583cf4b418,
title = "Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma",
abstract = "We performed p53 immunostaining in 82 invasive breast carcinomas by using two commercially available antibodies, one of which (DO7) was employed in formalin-fixed paraffin-embedded sections. The other antibody (PAb1801) was evaluated in corresponding acetone-fixed cryostat sections. A greater percent of cases were immunostained with DO7 compared to PAb1801 (52{\%} vs 33{\%}); however, the staining was more often heterogeneous (6-50{\%} cells positive) or focal (≤5{\%} cells positive) with DO7 (9{\%} vs 31{\%}). To investigate the genetic relevance of p53 immunostaining, single-strand conformational polymorphism (SSCP) analysis and DNA sequencing were performed on exons 2-11 by using archival tissue samples of 18 cases that were selected on the basis of certain immunostaining patterns. Two (33{\%}) of six tumors with negative staining for DO7 had gene sequence mutations; however, one of these mutations was a base-pair deletion that caused a reading-frame shift and the other was a base-pair insertion that resulted in a stop codon. Both of these tumors exhibited immunostaining with PAb1801, although it was weak and cytoplasmic in one case. Conversely, three (30{\%}) of 10 tumors showing immunoreactivity in 6-100{\%} of cells with both reagents lacked a gene sequence mutation. Of the remaining seven tumors that were positive by SSCP, six contained a point mutation resulting in a base-pair substitution. Despite repeat analyses, one of the cases positive by SSCP failed to demonstrate a mutation in the sequenced exons. Four (80{\%}) of five cases with heterogeneous DO7 immunoreactivity (that is, 6-50{\%} of nuclei positive) were positive for gene sequence mutation. Neither of two cases showing focal DO7 nuclear staining in <5{\%} of tumor cells contained a mutation in the sequenced exons, and neither of these cases was strongly positive with PAb1801. Staining for either antibody was significantly associated with adverse outcome, as determined by disease recurrence at 52 months median follow-up (DO7, p = 0.01; and PAb1801, p = 0.002, chi-squared test). We conclude that a variety of factors may account for discrepancies when immunohistology is used to evaluate p53 status. These include fixation artifacts, differing epitope specificities of monoclonal reagents, presence of immunohistologically 'silent' mutations and, possibly, aberrant overexpression of wild-type protein.",
keywords = "Breast carcinoma, p53 immunohistochemistry, SSCP analysis",
author = "Visscher, {Daniel W} and Sarkar, {Fazlul H.} and Shimoyama, {Rie K.} and Crissman, {John D.}",
year = "1996",
month = "9",
doi = "10.1097/00019606-199609000-00007",
language = "English (US)",
volume = "5",
pages = "187--193",
journal = "Diagnostic Molecular Pathology",
issn = "1052-9551",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma

AU - Visscher, Daniel W

AU - Sarkar, Fazlul H.

AU - Shimoyama, Rie K.

AU - Crissman, John D.

PY - 1996/9

Y1 - 1996/9

N2 - We performed p53 immunostaining in 82 invasive breast carcinomas by using two commercially available antibodies, one of which (DO7) was employed in formalin-fixed paraffin-embedded sections. The other antibody (PAb1801) was evaluated in corresponding acetone-fixed cryostat sections. A greater percent of cases were immunostained with DO7 compared to PAb1801 (52% vs 33%); however, the staining was more often heterogeneous (6-50% cells positive) or focal (≤5% cells positive) with DO7 (9% vs 31%). To investigate the genetic relevance of p53 immunostaining, single-strand conformational polymorphism (SSCP) analysis and DNA sequencing were performed on exons 2-11 by using archival tissue samples of 18 cases that were selected on the basis of certain immunostaining patterns. Two (33%) of six tumors with negative staining for DO7 had gene sequence mutations; however, one of these mutations was a base-pair deletion that caused a reading-frame shift and the other was a base-pair insertion that resulted in a stop codon. Both of these tumors exhibited immunostaining with PAb1801, although it was weak and cytoplasmic in one case. Conversely, three (30%) of 10 tumors showing immunoreactivity in 6-100% of cells with both reagents lacked a gene sequence mutation. Of the remaining seven tumors that were positive by SSCP, six contained a point mutation resulting in a base-pair substitution. Despite repeat analyses, one of the cases positive by SSCP failed to demonstrate a mutation in the sequenced exons. Four (80%) of five cases with heterogeneous DO7 immunoreactivity (that is, 6-50% of nuclei positive) were positive for gene sequence mutation. Neither of two cases showing focal DO7 nuclear staining in <5% of tumor cells contained a mutation in the sequenced exons, and neither of these cases was strongly positive with PAb1801. Staining for either antibody was significantly associated with adverse outcome, as determined by disease recurrence at 52 months median follow-up (DO7, p = 0.01; and PAb1801, p = 0.002, chi-squared test). We conclude that a variety of factors may account for discrepancies when immunohistology is used to evaluate p53 status. These include fixation artifacts, differing epitope specificities of monoclonal reagents, presence of immunohistologically 'silent' mutations and, possibly, aberrant overexpression of wild-type protein.

AB - We performed p53 immunostaining in 82 invasive breast carcinomas by using two commercially available antibodies, one of which (DO7) was employed in formalin-fixed paraffin-embedded sections. The other antibody (PAb1801) was evaluated in corresponding acetone-fixed cryostat sections. A greater percent of cases were immunostained with DO7 compared to PAb1801 (52% vs 33%); however, the staining was more often heterogeneous (6-50% cells positive) or focal (≤5% cells positive) with DO7 (9% vs 31%). To investigate the genetic relevance of p53 immunostaining, single-strand conformational polymorphism (SSCP) analysis and DNA sequencing were performed on exons 2-11 by using archival tissue samples of 18 cases that were selected on the basis of certain immunostaining patterns. Two (33%) of six tumors with negative staining for DO7 had gene sequence mutations; however, one of these mutations was a base-pair deletion that caused a reading-frame shift and the other was a base-pair insertion that resulted in a stop codon. Both of these tumors exhibited immunostaining with PAb1801, although it was weak and cytoplasmic in one case. Conversely, three (30%) of 10 tumors showing immunoreactivity in 6-100% of cells with both reagents lacked a gene sequence mutation. Of the remaining seven tumors that were positive by SSCP, six contained a point mutation resulting in a base-pair substitution. Despite repeat analyses, one of the cases positive by SSCP failed to demonstrate a mutation in the sequenced exons. Four (80%) of five cases with heterogeneous DO7 immunoreactivity (that is, 6-50% of nuclei positive) were positive for gene sequence mutation. Neither of two cases showing focal DO7 nuclear staining in <5% of tumor cells contained a mutation in the sequenced exons, and neither of these cases was strongly positive with PAb1801. Staining for either antibody was significantly associated with adverse outcome, as determined by disease recurrence at 52 months median follow-up (DO7, p = 0.01; and PAb1801, p = 0.002, chi-squared test). We conclude that a variety of factors may account for discrepancies when immunohistology is used to evaluate p53 status. These include fixation artifacts, differing epitope specificities of monoclonal reagents, presence of immunohistologically 'silent' mutations and, possibly, aberrant overexpression of wild-type protein.

KW - Breast carcinoma

KW - p53 immunohistochemistry

KW - SSCP analysis

UR - http://www.scopus.com/inward/record.url?scp=0029787441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029787441&partnerID=8YFLogxK

U2 - 10.1097/00019606-199609000-00007

DO - 10.1097/00019606-199609000-00007

M3 - Article

C2 - 8866232

AN - SCOPUS:0029787441

VL - 5

SP - 187

EP - 193

JO - Diagnostic Molecular Pathology

JF - Diagnostic Molecular Pathology

SN - 1052-9551

IS - 3

ER -